The level of detail in their intelligence summary gave us confidence to advance two internal programs. Easily one of our best consulting partners this year.

The EU trial landscape is notoriously crowded, but your team gave us a crystal-clear view of where to place our NSCLC and NET studies. We avoided low-recruitment regions entirely and accelerated our site activation strategy.

This was more than coverage—it was a strategic advantage. The real-time updates changed how our commercial and medical teams responded during the conference.

The consolidated intelligence report was boardroom-ready. Clean, precise, and packed with insights we used in our portfolio review.

Our R&D leadership used their analysis to shape our next-phase development decisions. It's rare to find CI partners who understand both science and strategy at this level.

Their competitor benchmarking reshaped how we positioned PCRun. The insights on cost sensitivity and workflow simplicity directly influenced our go-to-market strategy. It’s rare to see research translate this cleanly into action.

The rigor behind their methodology was impressive. Building a fully structured database of epidemiology, marketed therapies, and competitive landscape for over 100 indications is no small feat. The final 10-indication profiles were concise, data-rich, and exactly what our executive team needed.